Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2008-07-01
2008-07-01
Goldberg, Jeanine A. (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S006120, C435S091200, C536S023100, C536S023500, C536S024310, C536S024330
Reexamination Certificate
active
07393643
ABSTRACT:
This invention provides the identification of a truncation polymorphism of the mdr1 gene that is linked to ivermectin sensitivity in subjects, such as collies. Also provided are methods for detecting drug transport sensitivity in a subject, and animal models and in vitro cell systems using cells from animals having an mdr1 truncation.
REFERENCES:
patent: 5583008 (1996-12-01), Johnson et al.
patent: 6790621 (2004-09-01), Mealey et al.
patent: WO 94/26115 (1994-11-01), None
patent: WO 98/13072 (1998-04-01), None
patent: WO 98/14615 (1998-04-01), None
patent: WO 00/46347 (2000-08-01), None
patent: WO 00/52144 (2000-09-01), None
patent: WO 01/09183 (2001-02-01), None
Brown et al. of J. Tropical Medicine and Parasitology, 1998, 92: S61-S64.
Mealey et al. Pharmacogenetics 2001, 11:727-733.
van Helvoort et al., Cell, 1996, 87: 507-517.
Schinkel et al., Cell 77: 491-502.
Sparreboom et al., 1997, PNAS 94: 2031-2035.
Paul et al. (Veterinary Parasitology, vol. 121, pp. 285-291, 2004).
Takara et al. (Biol. Pharm. Bull. vol. 25, No. 6, pp. 771-778, 2002).
Griffin et al. (J. Vet. Pharmacol. Therap. vol. 28, pp. 257-265, 2005).
Geyer et al. (J. Vet Pharmacol. Therp. vol. 28, pp. 95-99, 2005).
Taub et al. (Drug Metabolism and Disposition, vol. 33, pp. 1679-1687, 2005).
Mealey et al. (JAVMA, vol. 223, No. 10, p. 1453,Nov. 2003).
Henik et al. (J. Vet. Intern Med, vol. 20, pp. 415-417, 2006).
Brown et al, “Changes in the use profile of Mectizan: 1987-1997,”Journals of Tropical Medicine&Parasitology92(1):S61-S64, 1998.
Campbell et al, “Molecular cloning and characterization of canine metalloproteinase-9 gene promoter,”Gene273(1):81-87, 2001 Abstract Only.
Carver et al, “Mutagenicity Testing in Mammalian Cells,”Mutation Research72:207-230, 1980.
Decleves et al, “A new polymorphism (N21D) in the exon 2 of the human MDR1 gene encoding the P-glycoprotein,”Human Mutation15(5):486, 2000.
Fassler et al, “Evaluation of the safety of ivermectin administered in a beef-based formulation to ivermectin-sensitive Collies,”J Am Vet Med Assoc199(4):457-460, 1991, Abstract Only.
Hoerauf et al, “Tetracycline therapy targets intracellular bacteria in the filarial nematodeLitomosoides sigmodontisand results in filarial infertility,”J Clin Invest103(1):11-17, 1999.
Hoffmeyer et al, “Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.”PNAS97(7):3473-3478, 2000.
Jun et al., “Insertion of a retroviral solo long terminal repeat in mdr-3 locus disrupts mRNA splicing in mice,”Mammal. Gen.11(10):843-848, Oct. 2000.
Kadoi, “Establishment of a canine monocyte cell line,”New Microbiol23(4):441-444, 2000 Abstract Only.
Kim et al, “The Drug Transporter P-glycoprotein Limits Oral Absorption and Brain Entry of HIV-1 Protease Inhibitors,”J Clin Invest101(2):289-294, 1998.
Knutsen et al, “Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene,MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory All,”Genes, Chromosomes and Cancer23(1):44-54, 1998 Abstract Only.
Lankas et al, “P-Glycoprotein Deficiency in a Subpopulation of CF-1 Mice Enhances Avermectin-Induced Neurotoxicity,”Toxicology and Applied Pharmacology143:357-365, 1997.
Martinez et al, “Neuromuscular Effects of Doxacurium Chloride in Isoflurane-Anesthetized Dogs,”Veterinary Surgery27:279-283, 1998 Abstract Only.
Mayer et al, “Full Blockade of Intestinal P-glycoprotein and Extensive Inhibition of Blood-brain Barrier P-glycoprotein by Oral Treatment of Mice with PSC833,”J Clin Invest100(10):2430-2436, 1997.
Mealey et al., “Frequency of the mutant MDR1 allele associated with ivermectin sensitivity in a sample population of Collies from the northwestern United States,”Am. J. Vet. Res.63(4):479-481, Apr. 2002.
Mealey et al., “Ivermectin sensitivity in collies is associated with a deletion mutation of the mrd1 gene,”Pharmacogen.11(8):727-733, Nov. 2001.
Rohrer and Evans, “Binding characteristics of ivermectin in plasma from collie dogs,”Vet Res Commun14(2):157-165, 1990 Abstract Only.
Roulet et al., “MDR pharmacogenetics in dog. Molecular basis of antiparasitic drug sensitivity (Ivermectin) in collie dog.”ABC 2001—3rdFEBS Advanced Lecture CourseMar. 2001 (4 pages).
Ruetz et al., “Functional expression of P-glycoprotein encoded by the mouse mdr3 gene in yeast cells,”Proc. Natl. Acad. Sci. USA90(24):11588-11592, 1993.
Pippert et al., “The subpopulation of CF-1 mice deficient in P-glycoprotein contains a murine retroviral insertion in the mdr1a gene,”J. Biochem. Mol. Toxicol.15(2):83-89, 2001.
Schinkel et al, “Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporine A,”J Clin Invest96(4):1698-1705, 1995 Abstract Only.
Schinkel et al., “Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs,”Cell77(4):491-502, 1994.
Schinkel et al., “N-glycosylation and deletion mutants of the human MDR1 P-glycoprotein,”J. Biol. Chem.268(10):7474-7481, 1993.
Schinkel et al, “P-Glycoprotein in the Blood-Brain Barrier of Mice Influences the Brain Penetration and Pharmacological Activity of Many Drugs,”J Clin Invest97(11):2517-2524, 1996.
Smit et al, “Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure,”J Clin Invest104(10):1441-1447, 1999.
Smith et al, “P-Glycoprotein Efflux at the Blood-Brain Barrier Mediates Differences in Brain Disposition and Pharmacodynamics between Two Structurally Related Neurokinin-1 Receptor Antagonists,”JPET298(3):1252-1259, 2001.
Suzuki and Sugiyama, “Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine,”Euro. J. Pharma. Sci.12:3-12, 2000.
Tranquilli et al, “Ivermectin plasma concentrations in collies sensitive to ivermectin-induced toxicosis,”Am J Vet Res50(5):769-770, 1989 Abstract Only.
Umbenhauer et al, “Identification of a P-Glycoprotein-Deficient Subpopulation in the CF-1 Mouse Strain Using a Restriction Fragment Length Polymorphism,”Toxic. Appl. Pharma.146:88-94, 1997.
Vaughn et al, “Determination of homovanillic acid, 5-hydroxyindoleacetic acid and pressure in the cerebrospinal fluid of collie dogs following administration of ivermectin,”Vet Res Commun13(1):47-55, 1989 Abstract Only.
http://www.dog-tracker.com/forums/vet/messages/10052.shtml, 7 pages, printed Nov. 18, 2000.
http://www.faqs.org/faqs/dogs-faq/breeds/collies, 2 pages, printed Nov. 18, 2000.
http://www.golden-retriever.com/heartwrm.html, 4 pages, printed Nov. 18, 2000.
Goldberg Jeanine A.
Klarquist Sparkman LLP.
Washington State University Research Foundation
LandOfFree
Method of detecting ivermectin sensitivity in a canine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of detecting ivermectin sensitivity in a canine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of detecting ivermectin sensitivity in a canine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2811619